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Epigenetic drugs modify DNA methylation and are used in refractory anemia with excess of blasts
(RAEB). These drugs may reactivate anti-oncogene expression and restore a normal phenotype instead of
inducing antitumor toxicity, although they also have immunosuppressive effects on T-lymphocytes [1] In
RAEB and acute myeloid leukemia, a defect in natural killer (NK) cell cytotoxicity has been shown, which
relies on abnormal expression of activating receptors. Previous study has shown that 5-azacytidine
impaired mRNA synthesis and induced apoptosis in NK cells [2]. In this study we investigated the effect
of the demethylating drug 5-azacytidine (Vidazas) on NK receptors with the hypothesis that
demethylation of the promoters of activating NK receptor genes induces gene reactivation and thus
may increase their expression.
& 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Letter to editor
Despite recent progress in approach of malignant haemopa-
thies, their prognosis frequently remains poor due to the difﬁculty
to achieve complete remission (CR) and to the high risk of relapse.
Immunotherapy could thus be of great interest in this setting.
Speciﬁc immunotherapy is mainly challenged by the defect of
expression of major histocompatibility complex (MHC) molecules
frequently observed in cancer cells, together with the progressive
selection of cancer clones that have lost their MHC molecules and
thus escape from immune control by speciﬁc T-lymphocytes. In
sharp contrast, natural killer (NK) cells are able to kill target cells
in a MHC-independent way, i.e. these cells “sense” the absence or
abnormal expression of MHC molecules to express their cytolytic
capacities, provided that tumor cells express ligands for NK
activating receptors (for review, [3]). Among activating NK mole-
cules, the so-called natural cytotoxicity receptors (NCRs) NKp30/
NCR3, NKp44/NCR2 and NKp46/NCR1, together with NKG2D and
2B4/CD244 play a pivotal role in NK cytotoxicity and probably in
their anti-leukemia effect [4]. Since the expression of activating
molecules is down-regulated in myeloid malignancies, we
hypothesized that demethylating agents such as 5-azacytidine
[5], used in the treatment of RAEB and AML with o30% blast
inﬁltration in bone marrow, could contribute to the restoration of
a normal phenotype of NK.
The work described has been carried out in accordance with
The Code of Ethics of the World Medical Association (Declaration
of Helsinki). Blood samples were obtained, before any treatment,
from 6 patients with RAEB II after informed consent. The analysis
of PB was done less than 4 h after blood sampling, on whole blood
after red blood cell lysis (Q-PrepR lysing kit, Beckman-Coulter, Ville-
pinte, France). The NK cell population was deﬁned as CD3-/CD56þ .
The following mAbs were all obtained from Beckman-Coulter:
anti-CD3FITC (UCHT1), anti-CD56PC5 (N901-NKH1), anti-NCR1/
NKp46PE, anti-NCR2/NKp44PE, anti-NCR3/NKp30PE, anti-NKG2DPE,
anti-CD244(2B4,p38)PE. Triple staining was performed using
CD3FITC/CD56PC5 in addition with anti-NCR1/NKp46PE, anti-
NCR2/NKp44PE, anti-NCR3/NKp30PE. For cell surface staining, cells
(5105) were incubated for 20 min at 4 1C with 10 μL of the
corresponding antibodies for 100 μL of cell preparation. Flow
cytometry was performed on an Epics XLR ﬂow cytometer (Beck-
man-Coulter). The results are expressed as follows; percentages
correspond to (% positive cells – % isotype control), while the mean
ﬂuorescent intensities (MFI) correspond to the ratio (MFI positive
cells / MFI isotype control). Statistical analysis was performed
using the SPSS software (SPSS User's Guide. SPSS Inc, 1993).
Regarding the expression of NKp46/NCR1 (Fig. 1A and B), both
increased and decreased expression are observed depending on
patients. Interestingly, the expression of the inducible molecule
NKp44/NCR2 is clearly induced in 3 patients (PT1, PT2 and PT5)
both regarding the percentage and the MFI. In contrast, we
observed a decrease in the expression of NKp30/NCR3 in 3 patients
(PT1, PT2 and PT7). Regarding NKG2D, a modiﬁcation of expression
was observed only in 2 patients, with 1 increase (PT4) and
1 increase (PT3) regarding the percentage of expression, while
the MFI was decreased in most patients. Finally, we analyzed the
expression of 2B4/CD244. This molecule is expressed in almost
100% of NK cells, and this percentage was not modiﬁed by
5-azacytidine treatment. In sharp contrast, when considering the
MFI, we observed a drastic decrease from a mean MFI of 77731
versus 36715 (po0.05).
The low number of patient in our series precludes ﬁrm
conclusions. Nonetheless, the 3-month treatment by the demethy-
lating agent 5-azacitytine failed to restore or increase the expres-
sion of the NK activating molecules NCRs, NKG2D and 2B4/CD244,
the expression of the later being on the contrary signiﬁcantly
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down-regulated (decreased MFI in 6 out of 6 patients tested). Such
a drastic down-regulation of 2B4/CD244 has also been observed in
multiple myeloma but interestingly in this case only in bone
marrow but not in peripheral blood [6]. We did not check NK
cells phenotype in bone marrow of our RAEB patients since this
analyze was not part of standard treatment follow-up. On the
other hand, we failed to detect any increase in the inhibitory
receptors we tested (CD158a, CD158b, CD158e, CD158i, CD159a, data
not shown). Since the 2B4/CD244 is an important co-activating
molecule for the NK, via its interaction with the EBV-inducible
% NKG2D MFI NKG2D
% 2B4/CD244 MFI 2B4/CD244
Fig. 1. Expression of activating receptors on Natural Killer cells expressed as percentage of positive cells (left panels) and mean ﬂuorescence intensity (MFI, right panels) for
NKp46 (A and B), NKp44 (C,D), NKp30 (E and F) NKG2D (G and H) and 2B4/CD344 (I and J). Data are expressed as the percentage of positive cells or of MFI after subtraction of
the negative isotype control. Black bars correspond to analysis before treatment, white bars after 3 cycles of 5-azacytidine treatment, and gray bars (only patient PT4)
analysis after 6 cycles of 5-azacytidine. PT: patient.
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CD48 molecule, we can speculate that 5-azacytidine treatment
could also contribute to immune deﬁciency via the inhibition of
this co-activating pathway, although the rate of infection observed
under 5-azacytidine did not increase in comparison with the other
therapeutic options available for these patients [7] and was at least
in part dependent on myelodysplasia characteristics, such as
unfavorable cytogenetics [8]. In addition, these data could suggest
that the methylation status is probably not the central mechan-
isms for the NCRs and NKG2D transcriptional regulation, although
the exact pattern of demethylation induced by 5-azacytidine is not
entirely analyzed and cannot infer drug efﬁciency. Finally, our data
also argue for the use of concomitant immune-stimulatory
approaches such as lenalidomide [9] or other IMIDs class drugs
in the treatment of RAEB or AML, in order to associate the
supposed differentiation effects of demethylating agents with
the development of an efﬁcient anti-leukemic innate immune
response.
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